Clinical trials: Sintilimab
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Unresectable Gastric Cancer
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally…
- Trial name
- NCT05385809
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
Hepatocellular Carcinoma Non-resectable
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of…
- Trial name
- NCT05530785
- Testing
- radiotherapy combined with sintilimab and bevacizumab biosimilar
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yongchang Zhang
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal…
- Trial name
- NCT06973343
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital
Sebaceous Gland Carcinoma
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant therapy with Sintilimab combined with Disitamab Vedotin in patients with locally advanced, resectable or potentially resectable sebaceous gland…
- Trial name
- NCT07740993
- Testing
- Sintilimab, disitamab vedotin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
NSCLC Stage IV
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.
- Trial name
- NCT04106180
- Testing
- GM-CSF, Sintilimab, SBRT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Fudan University
Gastric Cancer
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.
- Trial name
- NCT06054906
- Testing
- sintilimab+metronomic PLOF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huashan Hospital
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-small Cell Lung Cancer
Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy
- Trial name
- NCT04144582
- Testing
- Sintilimab Combined With Docetaxel Monotherapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Yongchang Zhang
Hepatocellular Carcinoma
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.
- Trial name
- NCT05010434
- Testing
- Sintilimab and Bevacizumab Combined with Radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Gastric cancer with retroperitoneal lymph node metastasis was considered as unresectable, to improve these patients' prognosis, we designed systematic conversion therapy including immunotherapy and chemoradiotherapy.
- Trial name
- NCT05002686
- Testing
- Sintilimab, Albumin-Paclitaxel, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Gastric Carcinoma, Gastric Neoplasm
The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes.
- Conditions
- Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT06702683
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Lin Liu
Advanced Endometrial Cancer
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
- Trial name
- NCT06584032
- Testing
- fruquintinib, sintilimab, paclitaxel
- Where
- 17 sites in China
- Volunteers
- 412 people
- Sponsor
- Hutchmed
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Primary Pulmonary Lymphoepithelioma-like Carcinoma, Lung Cancer
Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma
The trial was designed to explore the safety and efficacy of sintilimab combined with gemcitabine and carboplatin in the treatment of advanced LELC.
- Trial name
- NCT04312204
- Testing
- Sintilimab combined with Gemcitabine and Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhou Chengzhi